• Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset Realasset
moneycontrol.com

Home » News » Business

Dec 05, 2012, 11.07 AM | Source: PTI

Patent of cancer drug: SC reserves order on Novartis plea

The Supreme Court today reserved its order on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India.

Like this story, share it with millions of investors on M3

Patent of cancer drug: SC reserves order on Novartis plea

The Supreme Court today reserved its order on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India.

Post Your Comments

Share Cancel

The Supreme Court today reserved its order on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India.

A bench of justices Aftab Alam and Ranajan Prakash Desai reserved its verdict after marathon arguments which went on for months.

Novartis approached the apex court challenging the order of Chennai-based Intellectual Property Appellate Board (IPAB), which rejected its appeal against patent department's decision on Glivec.

The Comptroller General of Patent and Design had denied patent to Glivec on several grounds including its alleged failure to meet stipulations under sections 3(d) and 3(b) of the Indian Patent Law.

Section 3(d) restricts patents for already known drugs unless the new claims are superior in terms of efficacy.

Section 3(b) restricts patents for products that are against public interest and do not demonstrate enhanced efficacy over existing products.

Novartis India stock price

On February 11, 2016, Novartis India closed at Rs 671.25, down Rs 50.5, or 7 percent. The 52-week high of the share was Rs 982.00 and the 52-week low was Rs 539.95.


The company's trailing 12-month (TTM) EPS was at Rs 52.57 per share as per the quarter ended September 2015. The stock's price-to-earnings (P/E) ratio was 12.77. The latest book value of the company is Rs 313.51 per share. At current value, the price-to-book value of the company is 2.14.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Patent of cancer drug: SC reserves order on Novartis plea

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login